Zhitong Finance App News, Nanowei Technology (688690.SH) issued an announcement. The company expects to achieve net profit of about 218 million yuan in the first three quarters of 2026, an increase of about 110 million yuan over the same period last year (statutory disclosure data), an increase of about 102% over the same period last year.
During the reporting period, the company adhered to the business philosophy of “winning respect, and gaining the future through innovation”, firmly implemented the established development strategy, and deepened the main business of separation, purification, analysis and testing. The forward-looking layout covered a “full chromatographic ecosystem platform” covering products such as chromatographic fillers, chromatographic analysis columns, separation/analysis equipment, organic solvent resistant membrane systems, etc., to accelerate the transformation and upgrading from a single filler supplier to a “total solution provider for separation and purification”.
In the main biopharmaceutical separation and purification business, the “two-wheel drive, balanced development” market strategy will be fully implemented in 2026. On the basis of continuing to cultivate the two main application fields of polypeptide/GLP-1 and antibodies, we will actively seize the explosive growth of small nucleic acid drugs and the historical opportunities of domestic replacement of insulin chromatographic fillers, while further expanding potential markets for blood products, vaccines, and recombinant albumin. Through technological innovation of major products and quality improvement of key products, we consolidate our core competitive advantage, expand our share in the stock market, and actively expand opportunities in the incremental market.